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ORIGINAL ARTICLE
Background: There are few estimates of the effectiveness of long-
standing vaccination programs in developed countries. To fill this 
gap, we investigate the direct and indirect effectiveness of child-
hood vaccination programs on mortality at the population level in 
the Netherlands.
Methods: We focused on three communicable infectious diseases, 
diphtheria, pertussis, and poliomyelitis, for which we expect both 
direct and indirect effects. As a negative control, we used teta-
nus, a noncommunicable infectious disease for which only direct 
effects are anticipated. Mortality data from 1903 to 2012 were 
obtained from Statistics Netherlands. Vaccination coverage data 
were obtained from various official reports. For the birth cohorts 
1903 through 1975, all-cause and cause-specific childhood mortal-
ity burden was estimated using restricted mean lifetime survival 
methods, and a model was used to describe the prevaccination 
decline in burden. By projecting model results into the vaccination 
era, we obtained the expected burden without vaccination. Program 
effectiveness was estimated as the difference between observed and 
expected mortality burden.
Results: Each vaccination program showed a high overall effective-
ness, increasing to nearly 100% within 10 birth cohorts. For diph-
theria, 14.9% (95% uncertainty interval [UI] = 12.3%, 17.6%) of 
mortality burden averted by vaccination was due to indirect protec-
tion. For pertussis, this was 32.1% (95% UI = 31.3%, 32.8%). No 
indirect effects were observed for poliomyelitis or tetanus with −2.4% 
(UI = −16.7%, 7.1%) and 0.6% (UI = −17.9%, 10.7%), respectively.
Conclusion: Vaccination programs for diphtheria and pertussis 
showed substantial indirect effects, providing evidence for herd 
protection.
(Epidemiology 2018;29: 215–223)
Estimates of the effectiveness of long-standing vaccination programs provide insight into the value of these programs 
to public health.1 These insights are especially important for 
policy makers to motivate the continuation of these interven-
tions in this time of increasing vaccine hesitancy.2 Halloran 
and Struchiner3 described the overall effectiveness of a vac-
cination program as the ratio of the observed disease burden 
in a population with a vaccination program to that in a pop-
ulation without such a program. Such a measure takes both 
direct and indirect protection into account. Including indirect 
protection is important as it is the distinguishing feature of 
most vaccination programs.1,4–7 One approach for estimating 
vaccine program effectiveness would be to compare the bur-
den in the prevaccination era to the burden shortly after the 
introduction of the program.8 However, such comparisons for 
long-standing vaccination programs typically ignore secular 
trends in disease burden. Another approach is to construct a 
so-called counterfactual: the expected situation had the vac-
cination program not been introduced. One can then directly 
compare the observed disease burden (in the actual situation 
with an implemented vaccination program) to the expected 
burden in the same population without a vaccination program.
Constructing a counterfactual is not straightforward as 
diverse prevaccination dynamics need to be taken into account. 
This is especially the case for the earlier vaccines, such as diph-
theria, pertussis, tetanus, and polio, which were introduced in 
many developed countries in the mid-20th century. Indeed, few 
studies have focused on the effectiveness of early mass vaccina-
tion programs due to lack of data and proper analysis methods.
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Here we examine the population-level overall effec-
tiveness of vaccination programs on mortality burden and 
show that this overall effectiveness can be partitioned into 
a direct and indirect components. To do so, we make use of 
data from the Netherlands, where detailed mortality statistics 
are available from 1903 onward.9,10 In a previous analysis of 
these data, we showed that the all-cause childhood mortality 
burden declined exponentially over the 20th century, and that 
the mortality burden of many vaccine-preventable diseases 
declined at a similar exponential rate in the prevaccination 
period.9 Besides mortality data, information on vaccination 
coverage is available since the implementation of mass vacci-
nation programs in 1953. This makes the Dutch data uniquely 
equipped for investigating vaccination program effectiveness.
We pose the following research questions: is there evi-
dence for indirect effects of vaccination programs on mortal-
ity burden, and what is the magnitude of these indirect effects? 
To address these questions, we constructed counterfactual 
scenarios (i.e., scenarios in which vaccination programs were 
not implemented) using a model to describe trends in the pre-
vaccination era, and estimated program effectiveness with 
respect to childhood mortality burden in the first 2 decades 
after the start of mass vaccination in the 1950s. We quanti-
fied the magnitude of direct and indirect effects for three com-
municable vaccine-preventable diseases (diphtheria, pertussis, 
and polio), and one noncommunicable vaccine-preventable 
disease (tetanus), which serves as a negative control.11
METHODS
Childhood Mortality Burden
We used data on vaccination coverage and cause-specific 
mortality as previously reported in van Wijhe et al.9 Briefly, 
these data, spanning the period 1903–2012, were obtained 
from the national census bureau (Statistics Netherlands) and 
consist of the cause-specific number of deaths from various 
infectious diseases, including vaccine-preventable diseases. 
Deaths were stratified by year and age group (for 1903–1920: 
<1, 1–4, 5–13, 14–19, 20–29, 30–39, 40–49, 50–79, and 
≥80 years; for 1930–1940, the same age groups were avail-
able, except that 5–14 and 15–19 replaced 5–13 and 14–19; 
for 1941–2012, data were available by 5-year age group, with 
separate groups for <1 and ≥80 years). Here we focus on the 
mortality due to diphtheria, pertussis, tetanus, and polio dur-
ing the period 1903–1996. Data were available for the entire 
period, except for poliomyelitis which was included as a cause 
of death since 1920.
We quantified the childhood mortality burden as years 
of life lost before the age of 20. Each reported death was ran-
domly assigned a specific age within each age group and a 
birth cohort using multiple imputation methods. Cause-spe-
cific mortality burden was then calculated using restricted 
mean lifetimes survival analysis.12,13 This method estimates 
the years of life lost due to a specific cause up to a cut-off 
age within a competing risks framework. For our analysis, 
we choose a cut-off age of 20 years, as most mortality due to 
our diseases of interest occurred before that age. Each 1-year 
birth cohort between 1903 and 1975 was followed up to 20 
years of age. Cumulative incidence curves for each cause of 
death were constructed using the Aalen–Johansen estimator, 
and the corresponding age-specific childhood mortality bur-
den attributable to each cause was calculated from the area 
under the cumulative incidence curves.12,13 For more details, 
see eAppendix section 1; http://links.lww.com/EDE/B292, 
which provides more detail on the data preparation and sur-
vival analysis.
Vaccination Coverage
Vaccination coverage by birth cohort was obtained from 
various official reports by the Dutch Health Care Inspector-
ate (period 1949–1969) and the Dutch National Institute for 
Public Health and the Environment (period 1970–1975).9 
Missing cohorts (1953 for diphtheria, pertussis, and tetanus, 
and 1960–1961 for poliomyelitis) were linearly interpolated 
from adjacent birth cohorts. As far as data allowed, we used 
age-specific national vaccination coverage. In the early years 
of mass vaccination (before 1962), registration of vaccina-
tion coverage was less stringent, and it is unknown that how 
many vaccines each child had received at which age. For this 
period, vaccination coverage was determined from the num-
ber of children who had already been vaccinated at 1 year of 
age, and when entering kindergarten or elementary school. We 
assumed this calculated coverage represents the coverage at 
the ages of 3 months, 4 years, and 6 years of age, respectively. 
As the coverage metric, we used the proportion of children 
who had received at least one vaccine during their lifetime, 
and we assumed a 95% vaccine effectiveness against mortal-
ity regardless of the number of vaccine doses.14–16 In eFigures 
8–11; http://links.lww.com/EDE/B292, we present sensitivity 
analyses exploring the impact of this choice on our results.
Mass vaccination with the diphtheria toxoid vaccine 
started in 1953 in the Netherlands. Before the start of the mass 
vaccination program against diphtheria in 1953, vaccination 
was already ongoing and mainly administered at 4–14 years 
of age.17 In 1954, the diphtheria vaccine was combined with 
vaccines against pertussis and tetanus (DTP). Polio vaccina-
tion followed in 1957 with a staggered catch-up campaign of 
all children born since 1945. The polio vaccine was combined 
with DTP in 1962 (DTP-IPV) and was offered at 3, 4, 5, and 
11 months. Starting in 1965, revaccination with DT-IPV was 
offered at 4 and 9 years of age. Figure 1 shows the vaccination 
coverage by age (percentage of children vaccinated at least 
once) for each birth cohort since 1945. National vaccination 
coverage increased rapidly for each of these mass vaccination 
programs and reached 90% or higher within a decade after 
each vaccine introduction.9
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Modeling Overview
We estimated the overall effectiveness of a vaccination 
program on mortality, by comparing the observed childhood 
mortality burden with the expected mortality burden had the 
vaccination program not been introduced, i.e., the counter-
factual. To capture overall prevaccination trend in childhood 
mortality burden, the counterfactual model was based on two 
components: the exponential decline in all-cause childhood 
mortality burden and contribution of a specific disease to 
this all-cause childhood mortality burden. The exponential 
decline was modeled by fitting a linear regression model to 
log-transformed prevaccination all-cause childhood mortal-
ity burden over birth cohorts 1903–1940. The cause-specific 
contributions to the all-cause childhood mortality burden 
were calculated for each age separately as the ratio of the 
age- and cause-specific mortality burden to the total all-cause 
childhood mortality burden. We assumed that the age-specific 
contributions were constant in the prevaccination period (see 
eAppendix section 2; http://links.lww.com/EDE/B292, where 
we show that there were no relevant age trends in the prevacci-
nation period). To reflect uncertainty, the age-specific contri-
butions of each vaccine-preventable disease were resampled 
from the prevaccination period with a higher sampling weight 
for more recent birth cohorts. The distribution of the rate of 
exponential decline was obtained using the semiparametric 
bootstrap by resampling residuals (see  eFigure 1; http://links.
lww.com/EDE/B292, for the distribution of parameters used 
in constructing the counterfactual).
We extrapolated the counterfactual model from birth 
cohort 1948 up to and including the 1975 birth cohort. The overall 
vaccination program effectiveness in terms of mortality burden 
averted was defined as the ratio of observed and counterfactual 
childhood mortality burden. By incorporating vaccination cover-
age and vaccine effectiveness in the estimation, direct and indi-
rect effects of vaccination programs can be distinguished. The 






















































































































FIGURE 1. Vaccination coverage by 
age and birth cohort, the Netherlands, 
1948–1975. Vaccination coverage in 
the Netherlands for (A) diphtheria; 
(B) pertussis; (C) poliomyelitis; and 
(D) tetanus. Vaccination coverage is 
defined as the proportion of children 
having received at least one dose dur-
ing their lifetime.
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vaccination coverage and vaccine effectiveness (i.e., the expected 
proportion of children at a specific age who are immunized). 
Indirect effects were defined as the remaining childhood mortal-
ity burden averted after subtracting direct effects. The model is 
described in more detail in the following sections.
Counterfactual Model
We constructed the counterfactual by projecting the 
exponential decline forward from the start of mass vaccina-
tion programs, assuming the rate of decline in childhood mor-
tality burden, r, and the relative contribution of cause i to the 
all-cause childhood mortality burden at age a, pi,a, remained 
constant at their prevaccination values (see eAppendix section 
2; http://links.lww.com/EDE/B292). In the following, we indi-
cate the counterfactual by superscript c = 0 and the observed 
situation by c = 1. Let y0 be the all-cause childhood mortality 
burden in birth cohort t0, then for each birth cohort with birth 
year t, the age-specific counterfactual childhood mortality 
burden was calculated as follows:






− −( )( )=0 0 0  (1)
Both y0 and r were estimated by fitting a linear regression 
model to the log-transformed all-cause childhood mortal-
ity burden in the prevaccination period 1903–1940 (i.e., the 
intercept and the regression coefficient for birth cohort). The 
distributions of r and y0 were obtained using semiparametric 
bootstrap by resampling residuals. We assumed pi,a remained 
constant in the counterfactual situation, assuming the hypothe-
sis that the relative contribution did not change had vaccination 
programs not been introduced. We estimated pi,a for each birth 
cohort in the prevaccination period by dividing the age-specific 
years of life lost due to cause i by the all-cause years of life lost. 
To reflect uncertainty, pi,a was resampled from the distributions 
in the prevaccination periods with a higher weight for more 
recent birth cohorts: 1903–1930 for diphtheria; 1903–1940 
for pertussis; 1920–1940 for poliomyelitis; and 1903–1940 for 
tetanus (we excluded the Second World War).
Overall, Direct, and Indirect Program 
Effectiveness
The overall effectiveness of a vaccination program for 
cause i in birth cohort t up to age τ can be defined as the ratio 
of the observed mortality burden, Y ti a
c
,
= ( )1 , and the expected 
mortality burden in the counterfactual, Y ti a
c
,
= ( )0 .18
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The overall program effectiveness can also be parti-
tioned into the direct and indirect program effectiveness: 




, , ,( )= ( )+ ( ) . The expected direct program 
effectiveness is the product of the vaccine effectiveness, 
v, and the vaccination coverage at age a, Ca(t), such that 
E t vC ti a
direct
a, ( )= ( ) . The indirect program effectiveness, defined 
here as any reduction in mortality burden not explained by 
direct protection (in other words, the difference between the 
observed and expected mortality burden if only direct protec-
tion would play a role), can then be calculated as follows:
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We calculated the indirect effects of vaccination programs 
using a vaccine effectiveness against mortality of 95% for 
all vaccines. Varying the vaccine effectiveness had little 
qualitative and quantitative impact on our results other than 
increasing or decreasing the estimated indirect effects slightly 
(eFigure 8–10; http://links.lww.com/EDE/B292). Uncertainty 
intervals reflect the uncertainty inherent in the imputation 
of single-year ages from age group–specific data (Figure 2, 
shaded areas), combined with the resampling of prevacci-
nation period pi,a, and bootstraps of r and y0, yielding 95% 
uncertainty intervals. All analyses were performed in R statis-
tical programming environment, version 3.2.0 (R Foundation 
for Statistical Computing, Vienna, Austria).
RESULTS
Figure 2 shows the observed childhood mortality bur-
den along with the model fit to the prevaccination period and 
the estimated counterfactual (the situation had vaccination 
programs not been introduced). Our model adequately cap-
tures the observed prevaccination childhood mortality burden. 
Upon the start of mass vaccination, the counterfactual and 
observed childhood mortality burdens rapidly diverge. For 
pertussis (and to a lesser extent poliomyelitis), this divergence 
starts several cohorts before the start of mass vaccination. 
Because we look at birth cohorts, this early divergence may be 
due to indirect effects from vaccination of later birth cohorts or 
due to unregistered vaccination. This would result in a decline 
in mortality burden before the start of mass vaccination.
The overall effectiveness of vaccination programs 
against diphtheria, pertussis, poliomyelitis, and tetanus 
increased rapidly after the start of mass vaccinations and 
reached near 100% within 10 birth cohorts for each vaccine-
preventable disease (Figure 3).
Figure 4 shows the estimated direct and indirect vac-
cination program effectiveness in the Netherlands up to and 
including the 1975 cohort for diphtheria, pertussis, poliomy-
elitis, and tetanus. Mainly diphtheria and pertussis showed 
signs of indirect protection, with a maximum estimated indi-
rect effect of 0.25 (95% uncertainty interval [UI] = 0.24, 0.25) 
in birth cohort 1960 for diphtheria, and 0.62 (UI = 0.54, 0.69) 
in birth cohort 1951 for pertussis. Over time, as the proportion 
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of children who got vaccinated increased and the direct pro-
gram effectiveness increased, the indirect program effective-
ness for diphtheria and pertussis diminished. We expected to 
see indirect effects for poliomyelitis, but there was no clear 
evidence of indirect effects as in most birth cohorts, the uncer-
tainty intervals are broad and overlap with zero. No indirect 
effects were observed for tetanus, which is to be expected as it 
is not a communicable disease. By birth cohort 1965, almost 
no mortality burden was observed due to pertussis, diphtheria, 
poliomyelitis, or tetanus and the indirect program effective-
ness is reduced to the complement of the direct program effec-
tiveness (equation 3); hence, the small, positive value seen in 
all plots between the 1965 and 1975 birth cohorts.
Overall, since birth cohort 1948 and up to the 1975 
birth cohort, 14.9% (95% UI = 12.3%, 17.6%) of all child-
hood mortality burden averted due to diphtheria vaccina-
tion was due to indirect protection (Figure 4 and eFigure 2; 
http://links.lww.com/EDE/B292, which shows the averted mor-
tality burden due to indirect effects). For pertussis, 32.1% (95% 
UI = 31.3%, 32.8%) was due to indirect protection. For poliomy-
elitis and tetanus, this was −2.4% (UI = −16.7%, 7.1%) and 0.6% 
(UI = −17.9%, 10.7%), respectively.
DISCUSSION
According to our analysis, there are substantial indirect 
effects of mass vaccination against diphtheria and pertussis 
on childhood mortality burden, and program effectiveness 
was considerably higher than would be expected based on 
direct effects of vaccination alone. These indirect effects were 
especially high at the start of mass vaccination when vaccine 
coverage was still low; up to 25% of the averted diphtheria 
mortality burden was due to indirect effects and up to 62% for 
pertussis. These results provide evidence for herd protection, 









































































































































































FIGURE 2. Observed and estimated 
childhood mortality burden per live 
birth, the Netherlands, 1903–1975. 
The observed (solid), fitted (dashed), 
and counterfactual (dotted) (equa-
tion 1) years of life lost before the age 
of 20 per live birth by birth cohort in 
the Netherlands for (A) diphtheria; (B) 
pertussis; (C) poliomyelitis; and (D) 
tetanus. Lines indicate medians and 
95% uncertainty intervals.
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vaccination programs when vaccination coverages (and direct 
effects) were still relatively low.
We did not observe indirect effects due to vaccination 
against poliomyelitis. This was unexpected and may be due 
to the low number of observed deaths or due to the regular 
epidemics in the prevaccination period, which increased the 
uncertainty in our analysis. The staggered catch-up campaign 
of all children 15 years old and younger initiated in 1957, 
together with the broad age distribution of deaths due to 
poliomyelitis, further increased the width of the uncertainty 
intervals for both direct and indirect program effectiveness. 
Although we did estimate a high overall effectiveness of vac-
cination programs (Figure 3), our method may not be sensitive 
enough to detect indirect effects for poliomyelitis. It is likely 
that any indirect effects are more apparent in morbidity data 
than mortality. Here we restricted our analysis to mortality 
data, as these detailed data have been systematically collected 
for long-time periods. Similarly, indirect effects for pertussis 
and diphtheria, although present in mortality statistics, may be 
more pronounced in morbidity data.
We included tetanus, a noncommunicable vaccine-pre-
ventable disease, as a negative control for which we expect no 
indirect protection; indeed, we observed no indirect effects. 
To further check our calculation, we verified that the overall 
program effectiveness (equation 2) over the prevaccination 
period was zero (Figure 3). If our model performs well, the 
“overall program effectiveness” in the prevaccination period 
should fluctuate around the null and rapidly increase from the 
start of mass vaccination. This was the case for each vaccine-
preventable disease in our study period (a decline can be seen 
for diphtheria during the Second World War when large epi-
demics swept across Europe19). This finding, together with the 
near-zero estimate of indirect protection for the tetanus vac-
cination program, gives credence to our methodology.
There are several limitations and possible biases to 
our approach. First of all, our estimated counterfactual may 
be overestimated due to other, unaccounted for, factors unre-
lated to vaccination that also impact upon childhood mortality 
burden, most notably the increasing use of antibiotics around 
the time mass vaccination programs started. The impact of 
antibiotics is partially taken into account by the exponential 
decline in the all-cause childhood mortality burden, but may 
still show residual impact. This would lead to an overestima-
tion of our indirect effects. To investigate the potential impact 
of antibiotics on our results, we performed additional analyses 






























































































































































































s Vaccination coverage at one year of age
TetanusD
FIGURE 3. Overall vaccination pro-
gram effectiveness and vaccination 
coverage, the Netherlands, 1903–
1975. Overall program effective-
ness and vaccination coverage in the 
Netherlands for (A) diphtheria; (B) 
pertussis; (C) poliomyelitis; and (D) 
tetanus. Lines indicate medians and 
95% uncertainty intervals for the pre-
vaccination period (dashed) and the 
vaccination period (solid). Overall 
program effectiveness is defined as 
the ratio of averted childhood mortal-
ity burden to the expected childhood 
mortality burden had vaccination 
programs not been introduced (equa-
tion 2). The dashed lines represent 
the same calculation carried over to 
the prevaccination as a control. Vac-
cination coverage at 1 year of age is 
indicated by the diamond symbols, 
where open symbols represent inter-
polated data points. Here we assume 
a vaccine effectiveness against mortal-
ity of 95%.
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for details on the sensitivity analysis) in which we assume that 
antibiotics reduce the mortality burden in the counterfactual 
either by a constant or by increasing the rate of exponential 
decline. These analyses indicated that our results are sensitive 
to the influence of antibiotics, specifically if they influence 
mortality burden by increasing the exponential decline. How-
ever, even at a moderately high impact of antibiotics, indi-
rect effects are still present for pertussis and diphtheria. These 
effects decrease rapidly as the effect of antibiotics increases. 
Although our results are influenced by the potential reduction 
in mortality burden due to antibiotics (and other prevention 
measures than vaccination), if their impact is limited, indirect 
effects remain apparent, especially at lower levels of vaccina-
tion coverage.
Second, we assumed that the contributions of vaccine-
preventable diseases to the total mortality burden remained 
constant in the counterfactual. This is a reasonable assumption 
for most vaccine-preventable diseases, given their small and 
relatively constant contributions to the total mortality burden 
in the prevaccination period.9 The constancy assumption is 
also attractive as one would expect the cause-specific mortal-
ity burden to decline at a similar rate to the total mortality 
burden. In additional analyses, we tested whether there were 
any age-specific trends in the prevaccination period (see eAp-
pendix section 2; http://links.lww.com/EDE/B292). We did 
not find significant trends in the prevaccination period; how-
ever, any effects of existing trends would be overwhelmed by 
the existing uncertainty in the analysis. Our assumption of a 
constant contribution from all vaccine-preventable diseases to 
the counterfactual seems justified, and allows us to restrict the 
model to the decline in all-cause mortality, obviating the need 
to construct multiple disease-specific models.
Third, we assumed that the exponential decline in the 
prevaccination period would hold subsequent to the start of 
mass vaccination. Exponential declines in (childhood) mortal-













































































































































FIGURE 4. Direct and indirect vac-
cination program effectiveness, the 
Netherlands, 1948–1975. Direct 
(dashed) and indirect (solid) effec-
tiveness of vaccination programs in 
the Netherlands for (A) diphtheria; 
(B) pertussis; (C) poliomyelitis; and 
(D) tetanus. Lines indicate medians 
and 95% uncertainty intervals. Note 
that direct and indirect program 
effectiveness sum to the overall pro-
gram effectiveness. Here we assume a 
vaccine effectiveness against mortal-
ity of 95%.
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many developed countries besides the Netherlands.20 For our 
timeframe of interest—the period directly following the intro-
duction of mass vaccinations—it is unlikely that the trends in 
the counterfactual would look radically different than those 
in the prevaccination period, as these have been stable for the 
entire prevaccination period.
Another factor that may have biased our results is the 
uncertainty in registered vaccination coverage. Registration of 
vaccination coverage improved over time, and starting 1962, 
detailed records are available. In the early years of mass vacci-
nation, registration of vaccination status was often incomplete, 
and before the implementation of nationwide mass vaccina-
tion programs, there may have been substantial unregistered 
vaccination taking place.17 Our vaccination coverage data may 
thus underestimate actual coverage. In addition, it is unclear 
how many children and at what age children were vaccinated; 
a substantial number of vaccines may have been given to chil-
dren who were already immune due to natural infection. Our 
assumed vaccine effectiveness of 95% may therefore be unre-
alistic in the early part of the vaccination period. Decreasing 
vaccine effectiveness slightly increased the indirect effects, 
and increasing vaccine effectiveness slightly decreased the 
indirect effects (eFigures 8–11; http://links.lww.com/EDE/
B292). The interplay of these factors makes it difficult to 
determine if the vaccination coverage—and in extension the 
proportion immunized and our estimated indirect effects—is 
biased and in which direction.
This research focused on the population-wide direct and 
indirect effectiveness of vaccination programs on mortality 
in the Netherlands. Indirect protection is a well-established 
phenomenon in infectious disease epidemiology.7 However, a 
quantitative estimate of the magnitude of indirect protection 
compared with direct protection has been lacking for the older 
vaccination programs, and specifically, the literature on the 
population effectiveness of vaccination programs using popu-
lation-wide surveillance data is deficient.21 Other studies look-
ing into the population effectiveness of vaccination programs 
have mainly focused on contemporary vaccines such as menin-
gococcal serogroup C conjugate vaccines,22–24 multivalent 
pneumococcal conjugate vaccines,25,26 rotavirus vaccines,27,28 
Haemophilus influenza type b conjugate vaccines,29,30 and 
influenza vaccines.31 Our research provides a quantitative 
insight into the population direct and indirect effectiveness of 
older vaccination programs using already existing data sources.
Future research should focus on the effectiveness of vac-
cination programs on morbidity by including hospitalization 
or notification data. This is especially important for diseases 
such as poliomyelitis for which program effectiveness may not 
be well estimated using mortality data, and for which a major 
share of disease burden is attributed to long-term sequelae. 
Alternatively, our methods could be verified using mortality 
data from other countries. In addition, spatial heterogeneity 
should be accounted for, as vaccination coverage shows sub-
stantial geographical differences.32 This heterogeneity may 
provide more insight into the indirect effects of vaccination 
when comparing high- and low-coverage regions.
Our analysis shows that the indirect effects of the early 
vaccination programs for diphtheria and pertussis are pro-
nounced even in mortality statistics, indicating that for a 
proper appreciation of the impact of vaccination programs and 
the monitoring of their effectiveness, both direct and indirect 
effects should be taken into account.
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